Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancers|April 30, 2021
FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian CancersKatia A Mesquita, Reem Ali, Rachel Doherty, et al.
NPJ Precision Oncology|July 19, 2022
Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancersAdel Alblihy, Reem Ali, Mashael Algethami, et al.
Nature|April 15, 2005
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyHannah Farmer, Nuala McCabe, Christopher J Lord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1E Ruth Plummer, Mark R Middleton, Christopher Jones, et al.
Journal of Medicinal Chemistry|January 20, 2021
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)Zhuming Zhang, Peter J Connolly, Heng Keang Lim, et al.
Pediatric Blood & Cancer|September 17, 2013
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing ProgramHernan Carol, Richard Gorlick, E Anders Kolb, et al.
Molecular Cancer Therapeutics|March 2, 2021
Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate CancerJonathan R Branch, Tammy L Bush, Vineet Pande, et al.
Neuro-Oncology|October 8, 2024
MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastomaMagretta Adiamah, Bethany Poole, Janet C Lindsey, et al.
Bioorganic & Medicinal Chemistry Letters|September 8, 2009
Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTORKeith A Menear, Sylvie Gomez, Karine Malagu, et al.
Bioorganic & Medicinal Chemistry Letters|September 19, 2009
The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinaseKarine Malagu, Heather Duggan, Keith Menear, et al.
Pageof 3